For your patients with type 2 diabetes on monotherapy
when HbA
1c
levels begin to rise above 7 %
1,2,3
References: 1.
DeFronzo RA,
et al. Diabetes Care
2009;32:1649–55.
2.
Chacra AR,
et al. Int J Clin Pract
2009;63(9):1395–406.
3.
Hollander P,
et al. J Clin Endocrinol Metab
2009;94(12):4810–9.
S3 ONGLYZA
®
2.5 (Tablet). Each ONGLYZA
®
2.5 tablet contains saxagliptin hydrochloride equivalent to 2.5 mg saxagliptin free base. S3 ONGLYZA
®
5 (Tablet). Each ONGLYZA
®
5 tablet contains saxagliptin hydrochloride equivalent
to 5 mg saxagliptin free base. PHARMACOLOGICAL CLASSIFICATION:A.21.2 Oral hypoglycaemics. Reg. No. ONGLYZA
®
2.5 : 43/21.2/0608. Reg. No. ONGLYZA
®
5 : 43/21.2/0609. Ref: Reg. No. ONGLYZA
®
- EPI (28/07/11). ONGLYZA
®
is a registered trademark of Bristol-Myers Squibb. For full details relating to any information mentioned above please refer to the package insert. Bristol-Myers Squibb (Pty) Limited. Reg. No. 1956/001115/07. 47 van Buuren
Road, Bedfordview, 2008, South Africa. Tel: (011) 456 6400. Fax: (011) 4566579/80.
Date compiled: December 2011
